Core Viewpoint - Rosen Law Firm is reminding investors who purchased Rocket Pharmaceuticals securities between February 27, 2025, and May 26, 2025, of the upcoming lead plaintiff deadline on August 11, 2025, for a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Rocket Pharmaceuticals securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by August 11, 2025 [3]. - Investors are encouraged to select qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Case Background - The lawsuit alleges that Rocket Pharmaceuticals provided misleading statements regarding the safety and clinical trial protocol of RP-A501, concealing material adverse facts, including the risk of Serious Adverse Events (SAEs) [5]. - The company amended the trial protocol to include a new immunomodulatory agent without informing shareholders, leading to artificially inflated stock prices [5]. - When the true details became public, investors reportedly suffered damages due to the misleading information [5].

一、本周指数增强组合表现 沪深300指数增强组合本周超额收益-0.30%，本年超额收益7.76%。 中证500指数增强组合本周超额收益0.31%，本年超额收益9.34%。 中证1000指数增强组合本周超额收益0.39%，本年超额收益14.45%。 中证A500指数增强组合本周超额收益0.71%，本年超额收益9.03%。 二、本周选股因子表现跟踪 沪深300成分股中标准化预期外收入、特异度、单季EP等因子表现较好。 中证500成分股中标准化预期外盈利、特异度、SPTTM等因子表现较好。 中证1000成分股中DELTAROE、单季营利同比增速、DELTAROA等因子表 现较好。 中证A500指数成分股中特异度、预期EPTTM、单季营利同比增速等因子表 现较好。 公募基金重仓股中特异度、DELTAROE、DELTAROA等因子表现较好。 三、本周公募基金指数增强产品表现跟踪 沪深300指数增强产品本周超额收益最高0.87%，最低-0.57%，中位数 0.24%。 中证500指数增强产品本周超额收益最高0.90%，最低-0.68%，中位数 0.24%。 中证1000指数增强产品本周超额收益最高1.06%，最低-0.3 ...

证券研究报告 | 2025年07月12日 多因子选股周报 成长因子表现出色，中证 1000 指增组合年内超额 14.45% 核心观点 金融工程周报 国信金工指数增强组合表现跟踪 因子表现监控 以沪深 300 指数为选股空间。最近一周，标准化预期外收入、特异度、单季 EP 等因子表现较好，而 3 个月盈利上下调、一个月换手、一年动量等因子 表现较差。 以中证 500 指数为选股空间。最近一周，标准化预期外盈利、特异度、SPTTM 等因子表现较好，而单季 ROA、单季 ROE、三个月机构覆盖等因子表现较 差。 以中证 1000 指数为选股空间。最近一周，DELTAROE、单季营利同比增速、 DELTAROA 等因子表现较好，而预期 EPTTM、三个月机构覆盖、三个月 换手等因子表现较差。 以中证 A500 指数为选股空间。最近一周，特异度、预期 EPTTM、单季营 利同比增速等因子表现较好，而 3 个月盈利上下调、一个月换手、三个月换 手等因子表现较差。 以公募重仓指数为选股空间。最近一周，特异度、DELTAROE、DELTAROA 等因子表现较好，而 3 个月盈利上下调、三个月换手、一个月换手等因子表 现较差。 ...

7月11日晚间，易方达基金、华宝基金、平安基金、国联安基金等多家公募上报中证A500红利低波交易 型开放式指数证券投资基金(简称"中证A500红利低波ETF")，成为今年4月中证A500红利低波指数发布 后，首批申报的跟踪该指数的ETF。中证A500红利低波动指数，是从中证A500指数样本中选取50只连 续分红、股息率较高且波动率较低的证券作为指数样本，采用股息率加权，以反映中证A500指数样本 中股息率较高且波动率较低上市公司证券的整体表现。此外，今年4月中证指数公司还发布了中证A500 红利指数、中证A500红利增长指数、中证A500质量指数、中证A500红利质量指数。(新浪财经) ...

以下文章来源于睿知睿见 ，作者睿知睿见 睿知睿见 . 一个好的投资者，其能量一定的积极的，向上的，乐观的！ 别人看着他，就像看着太阳！ 他还能用朴 实易懂的语言，传递正确的投资理念！ 风险提示：本文所提到的观点仅代表个人的意见，所涉及标的不作推荐，据此买卖，风险自负。 作者： 睿智睿见 来源：雪球 昨天A股终于站上3500点了，虽然在3500点了，但很多人的持仓可能还在3100点，因为结构化行 情很显著。这对投资者是极大的考验。 3500点以后，市场整体就要奔着去年10月的高点挑战了。 但是请注意， 不大可能一鼓作气就拿下。 一、未来还要磨洋工 上次突破3500点是11月8日。那会全A的成交额在2.6万亿以上！ 这么高的成交额都没有快速突破，为啥？ 因为换手率是3.58%。 今天的成交额只有1.5万亿，换手率是1.2%。 股价=成交额/（换手率*自由流通股本） 两者相比，我们就能发现，现在换手率萎缩得更快，说明 配置资金占比又上了一个台阶。 配置资金买入时的市场特征就是： 低波、低换手，相对较低的成交额。 既然是配置资金占主导，那么市场大概率是走慢牛。继续磨洋工。 今天成交额居前的ETF全是A500，昨天跟大 ...

Group 1 - NetEase's first major single-player game, "Wanmin Changge: Three Kingdoms," was canceled shortly after its demo release, indicating a cautious approach to project viability based on market demand [4][17] - The success of "Black Myth: Wukong" has revitalized the single-player game market in China, showcasing its potential beyond direct sales revenue and changing perceptions about the quality of domestic single-player games [4][5] - The number of new F2P games in China is declining, with a reported drop of over 22% year-on-year in the first half of 2025, indicating a challenging environment for free-to-play titles [4][12] Group 2 - The single-player game market in China saw significant growth, with sales reaching approximately 10.22 billion yuan in 2024, largely driven by "Black Myth: Wukong," which alone generated around 9 billion yuan [7][9] - Despite the growth in single-player games, they still lag behind top F2P games in revenue, with "Honor of Kings" generating approximately 2.419 billion USD (about 17.359 billion yuan) in 2024 [9][10] - The cost of developing AAA games has become a significant challenge, with budgets often exceeding 100 million USD, leading to a focus on fewer, more secure projects by major publishers [18][20] Group 3 - The cancellation of "Wanmin Changge: Three Kingdoms" highlights the high development costs associated with single-player games, where a team of 70 could incur costs of around 150 million yuan over three years, necessitating substantial sales to break even [17][21] - The industry is witnessing a shift towards mid-tier 2A games and independent titles as viable options for developers, allowing for better cost control while still delivering creative content [21] - The current landscape suggests that the single-player game market may be entering a favorable era, where both creative aspirations and financial viability can coexist [21]

证券之星消息，截止2025年二季度末，基金经理陈奇旗下共管理2只基金，本季度表现最佳的为华富时代锐选混合A（016119），季度净值涨 1.84%。 | 在任基金 | 规模(亿元) | | 年化回报 | 2025年二季度涨幅 | 第一重合股 | 占浄値比 | | --- | --- | --- | --- | --- | --- | --- | | 华富时代锐选混合A | | 0.59 | -4.91% | 1.84% | 锦江在线 | 4.50% | | 016119 | | | | | 600650.SH | | | 华富时代锐选混合C | | 0.10 | -5.29% | 1.74% | 锦江在线 | 4.50% | | 016120 | | | | | 600650.SH | | 陈奇在担任华富物联世界灵活配置混合A（001709）基金经理的任职期间累计任职回报75.1%，平均年化收益率为10.27%。期间重仓股调仓次数共 有92次，其中盈利次数为49次，胜率为53.26%；翻倍级别收益有1次，翻倍率为1.09%。 以下为陈奇所任职基金的部分重仓股调仓案例： | 股票名称 | 调入季度 | 调出季度 ...

Core Viewpoint - Rocket Pharmaceuticals, Inc. is facing a class action securities lawsuit due to alleged securities fraud related to the safety and clinical trial protocol of its RP-A501 treatment, which resulted in significant stock price decline after the FDA placed a clinical hold on the study [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover losses for investors affected by alleged securities fraud between February 27, 2025, and May 26, 2025 [1]. - Defendants allegedly provided misleading statements about the safety of RP-A501 while concealing serious adverse events, including participant deaths during the clinical trial [2]. - Following the announcement of the FDA's clinical hold on May 27, 2025, Rocket's stock price plummeted from $6.27 to $2.33 per share, a decline of approximately 37% in one trading day [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the relevant timeframe have until August 11, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the U.S. [4].

NEW YORK, July 11, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") (NASDAQ: RCKT) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Rocket investors who were adversely affected by alleged securities fraud between February 27, 2025 and May 26, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/rocket-pharmaceuticals-i ...

证券研究报告 | 2025年07月11日 金融工程日报 沪指放量微涨，银行冲高回落，稀土、券商爆发 市场表现：今日(20250711) 大部分指数处于上涨状态，规模指数中中证 1000 指数表现较好，板块指数中科创 50 指数表现较好，风格指数中中证 500 成 长指数表现较好。非银、计算机、有色金属、钢铁、综合金融行业表现较好， 银行、建材、煤炭、纺织服装、交通运输行业表现较差。稀土、炒股软件、 稀土永磁、CRO、中国国际进口博览会等概念表现较好，玻璃纤维、覆铜板、 银行精选、电路板、央企银行等概念表现较差。 市场情绪：今日收盘时有 68 只股票涨停，有 14 只股票跌停。昨日涨停股票 今日收盘收益为 2.42%，昨日跌停股票今日收盘收益为-2.29%。今日封板率 66%，较前日下降 7%，连板率 29%，较前日下降 6%。 市场资金流向：截至 20250710 两融余额为 18737 亿元，其中融资余额 18605 亿元，融券余额 132 亿元。两融余额占流通市值比重为 2.2%，两融交易占市 场成交额比重为 9.4%。 折溢价：20250710 当日 ETF 溢价较多的是 A50 增强 ETF，ETF ...